Navigation Links
Sunesis to Present at Upcoming Conferences
Date:11/3/2008

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the following upcoming conferences:

Rodman & Renshaw 10th Annual Healthcare Conference

The New York Palace Hotel, New York

Wednesday, November 12, 2008

2:00 p.m. EST

Lazard Capital Markets 5th Annual Healthcare Conference

The St. Regis, New York

Tuesday, November 18, 2008

5:10 p.m. EST

BIO-Europe 2008

m:con Congress Center Rosengarten

Mannheim, Germany

Tuesday, November 18, 2008

9:15 a.m. CET / 3:15 a.m. EST

Interested parties may access a webcast of the Rodman & Renshaw and Lazard Capital presentations by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and th
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
2. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
3. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
6. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
7. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
8. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 Esperance Pharmaceuticals ... trial of lead candidate EP-100 in ovarian cancer patients ... designed to seek and destroy cancer cells that overexpress ... receptors are over-expressed in a wide range of cancers. ... Phase II trial of EP-100 were presented at ...
(Date:6/1/2015)... BOSTON , June 1, 2015  Berg, a ... data-driven, biological approach, presented clinical research from its trials ... solid tumors and preclinical data on triple negative breast ... the American Society of Clinical Oncology (ASCO), May 29 ... BPM 31510 is one of the ...
(Date:6/1/2015)... June 1, 2015  Albany Molecular Research ... that it has signed a collaborative agreement ... their structure-based drug discovery services to global ... the three-year agreement, AMRI gains access to ... capabilities. HarkerBIO,s customers will be able to ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... BEIJING, China, Oct. 2 /PRNewswire-Asia-FirstCall/ -- Yongye International,Inc. (Nasdaq: ... manufacturer,developer and distributor of Shengmingsu brand plant and animal ... announced its 2010-,2012 strategic plan. , ... and thus far in,2009, Yongye expects to achieve at ...
... ... with the addition of Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) ... Situational Leadership V (SLV) series specifically for biotech and specialty pharma companies. The new ...
... LAFAYETTE, Ind. - Researchers have overcome a major obstacle ... to create a new class of electronics that would ... Carbon nanotubes, which were discovered in the early 1990s, ... as well as ultra-thin "nanowires" for electronic circuits. The ...
Cached Biology Technology:Yongye International Announces 2010-2012 Strategic Plan 2Yongye International Announces 2010-2012 Strategic Plan 3Yongye International Announces 2010-2012 Strategic Plan 4Yongye International Announces 2010-2012 Strategic Plan 5Perceptum Group Announces New Situational Leadership V Series 2Better control of carbon nanotube 'growth' promising for future electronics 2Better control of carbon nanotube 'growth' promising for future electronics 3
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... patient,s body, stem cells intended to treat or cure ... they are no longer under the control of the ... solve this problem, according to a perspective article from ... a recent issue of the journal Cell Stem ...
... traffic lights the scourge of Britain,s roads! But now ... misery of motorists caused by the repair, maintenance and ... reveal how new technology will allow workers to virtually ... seminar at The University of Nottingham on June 11th ...
... popular belief, aggressive dogs are NOT trying to assert ... to research published by academics at the University of ... Journal of Veterinary Behavior, Clinical Applications and Research . ... interacting at a Dogs Trust rehoming centre, and reanalysing ...
Cached Biology News:Gene therapy could expand stem cells' promise 2Reducing the roadworks 2Reducing the roadworks 3Using 'dominance' to explain dog behavior is old hat 2
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Biology Products: